General Information of Drug (ID: DM6ENSJ)

Drug Name
Tralokinumab Drug Info
Synonyms CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca
Indication
Disease Entry ICD 11 Status REF
Atopic dermatitis EA80 Approved [1]
Ulcerative colitis DD71 Phase 3 [2]
Asthma CA23 Phase 1/2 [3]
Cross-matching ID
TTD Drug ID
DM6ENSJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Interleukin-13 (IL13)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lebrikizumab DMQP0X5 Severe asthma CA23 Phase 3 [6]
Dexpramipexole DM6KXAU Eosinophilic asthma CB02.0 Phase 3 [7]
Cendakimab DM9LSBJ Eosinophilic esophagitis DA24.1 Phase 3 [8]
SAR-156597 DMUICJD Idiopathic pulmonary fibrosis CB03.4 Phase 2 [9]
PEGylated pitrakinra DMBPJ9U Asthma CA23 Phase 2 [6]
Romilkimab DMYEZ5J Idiopathic pulmonary fibrosis CB03.4 Phase 2 [10]
QAX-576 DMUWFI7 Allergic rhinitis CA08.0 Phase 2 [11]
Anrukinzumab DMTG2O0 Asthma CA23 Phase 2 [12]
Dectrekumab DM1H7UK Idiopathic pulmonary fibrosis CB03.4 Phase 2 [11]
CNTO-5825 DMF8WAT Allergic asthma CA23.0 Phase 1 [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ICT-107 DMBIZ7H Brain cancer 2A00 Phase 3 [14]
ABT-308 DM6WN2D Eosinophilic esophagitis DA24.1 Phase 2 [15]
MB-101 DMLA1QD Recurrent glioblastoma 2A00.00 Phase 1 [16]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-13 (IL13) TT0GVCH IL13_HUMAN Inhibitor [4]
Interleukin 13 receptor alpha-2 (IL13RA2) TTMPZ7V I13R2_HUMAN Modulator [5]

References

1 FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761180.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8001).
3 ClinicalTrials.gov (NCT02085473) A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Tralokinumab When Delivered at Different Flow Rates to Healthy Volunteers
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.Am J Respir Cell Mol Biol.2014 May;50(5):985-94.
6 The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
7 Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019 Jun;46:29-33.
8 Biologics in eosinophilic gastrointestinal diseases. Ann Allergy Asthma Immunol. 2023 Jan;130(1):21-27.
9 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
10 A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
11 Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
12 Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900.
13 Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75(5):1289-98.
14 Clinical pipeline report, company report or official report of ImmunoCellular Therapeutics.
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)